BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Kemas kini terakhir: 10 jam lalu65.04
-1.46 (-2.20%)
| Penutupan Terdahulu | 66.50 |
| Jumlah Dagangan | 3,361,938 |
| Harga / Jualan (P/S) | 17.88 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BridgeBio Pharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 2.21 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 30 Jun 2026 | 13,260,971 |
| Viking Global Investors Lp | 30 Jun 2026 | 9,949,219 |
| Aisling Capital Management Lp | 30 Jun 2026 | 4,589,611 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |